Cohance Lifesciences Secures $18M Stake in NJ & Aruka Bio

Cohance Lifesciences is committing $18 million across two transactions to build out antibody-drug conjugate capabilities, a move that signals the growing pressure on CDMOs and specialty pharma manufacturers to establish credible high-potency biologics infrastructure before client demand outpaces available capacity.

The investments target NJ Bio and Aruka Bio, with both deals funded through internal accruals and expected to close by the end of September 2026. No external debt or equity raise is involved, which limits balance-sheet exposure while preserving operational flexibility during integration.

For plant heads and QA directors, the operational read on ADC scale-up is unambiguous: conjugation suites require dedicated containment engineering, cytotoxic handling protocols, and environmental monitoring programs that go well beyond standard 21 CFR Part 211 baseline requirements. Linker-payload combinations introduce potent compound classification obligations that must be addressed at the facility design stage, not retrofitted after regulatory review begins.

The regulatory pathway for ADC drug products also intersects with ICH Q10 pharmaceutical quality system expectations around process validation and change control, particularly when a CDMO is onboarding a new modality. Agencies have increased scrutiny on ADC manufacturing sites in recent inspection cycles, with observations frequently citing inadequate containment verification and gaps in sterility assurance for the final conjugated product.

Cohance's decision to acquire stakes rather than build greenfield capacity suggests a preference for accelerating time-to-GMP-readiness by absorbing existing infrastructure and technical teams, a strategy that compresses validation timelines but introduces its own due-diligence obligations around inherited quality systems and any open regulatory commitments at the target sites.

Completion of both transactions by September 2026 will mark the first measurable checkpoint for integration progress, with process validation alignment across the combined ADC platform the near-term deliverable that QA and regulatory leads at Cohance will need to prioritize.

Source: Media4Growth via Indian Pharma Post, 3 September 2026.